(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

ECKERDS PHARMACY

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

ECKERDS PHARMACY

ST13

US500000086941116

Class

35

Filing

86941116

Registration

5126063

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

41

Latest update

01/18/2026

Trademark type

Word

Nice classes

35

Filing date

03/15/2016

Registration date

01/17/2017

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

08/09/2022

Last transaction

01/18/2026

Responsible office

United States Patent and Trademark Office

Status code

701

Official register

Supplemental Register

Filing basis

Intent to use

First use anywhere

02/24/2016

First use in commerce

02/24/2016

Drawing code

4

Owner type

16

Owner location

BRADENTON, FL

Examiner

COHEN,ROBERT ANDREW

Law office

L30

Current location

TMEG LAW OFFICE 103

Holders and representatives

Holders

SUNSHINE RX LLC

Representatives

SUNSHINE RX LLC

Technical classification

Nice Classes

Class 35

Vienna Codes

No Vienna codes available.

Goods and services

Class 35

Retail pharmacy services

Publications

History of USPTO decisions and trademark events.

41 publications found

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

01/17/2026

NAS8

NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED

08/09/2022

8.OK

REGISTERED - SEC. 8 (6-YR) ACCEPTED

08/09/2022

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

08/02/2022

ES8R

TEAS SECTION 8 RECEIVED

03/04/2022

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

01/17/2022

R.SR

REGISTERED-SUPPLEMENTAL REGISTER

01/17/2017

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

12/13/2016

CNTA

APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER

12/02/2016

XAEC

EXAMINER'S AMENDMENT ENTERED

12/02/2016

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

12/02/2016

GNEA

EXAMINERS AMENDMENT E-MAILED

12/02/2016

CNEA

EXAMINERS AMENDMENT -WRITTEN

12/02/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

11/29/2016

AAUA

NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED

11/29/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

11/28/2016

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

11/28/2016

DMCC

DATA MODIFICATION COMPLETED

11/28/2016

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

11/27/2016

GNRT

NON-FINAL ACTION E-MAILED

11/27/2016

CNRT

NON-FINAL ACTION WRITTEN

11/27/2016

IUAA

USE AMENDMENT ACCEPTED

11/27/2016

AUPC

AMENDMENT TO USE PROCESSING COMPLETE

11/02/2016

IUAF

USE AMENDMENT FILED

11/02/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/25/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/25/2016

EAAU

TEAS AMENDMENT OF USE RECEIVED

10/24/2016

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

10/24/2016

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

10/21/2016

GNRT

NON-FINAL ACTION E-MAILED

10/21/2016

CNRT

NON-FINAL ACTION WRITTEN

10/21/2016

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/30/2016

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/30/2016

ALIE

ASSIGNED TO LIE

09/29/2016

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

09/15/2016

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

06/30/2016

GNRT

NON-FINAL ACTION E-MAILED

06/30/2016

CNRT

NON-FINAL ACTION WRITTEN

06/30/2016

DOCK

ASSIGNED TO EXAMINER

06/24/2016

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

03/18/2016

NWAP

NEW APPLICATION ENTERED

03/18/2016

Continuous trademark protection

Get notified about every new filing that threatens ECKERDS PHARMACY or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.